Tabling hydromorphone: Do we have it right?

Journal of Palliative Medicine

Volumn 13, Issue 4, 2010, Pages 365-366

  Davis, Mellar P ^a   McPherson, Mary Lynn ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; OXYCODONE;

ANALGESIA; CANCER PAIN; DRUG SAFETY; DRUG SUBSTITUTION; LETTER; PATIENT CONTROLLED ANALGESIA;

ANALGESICS, OPIOID; HUMANS; HYDROMORPHONE; MORPHINE; THERAPEUTIC EQUIVALENCY; TREATMENT FAILURE;

EID: 77951784492     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0366     Document Type: Letter

References (20)

1. Anderson R, Saiers JH, Abram S, Schlicht C: Accuracy in equianalgesic dosing: Conversion dilemmas. J Pain Symptom Manage 2001;21:397-406.
2. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S: Clinical application of opioid equianalgesic data. Clin J Pain 2003;19:286-297.
3. Fine PG, Portenoy RK, for the Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation: Establishing "best practices" for opioid rotation: Conclusions for an expert panel. J Pain Symptom Manage 2009;38:418-425.
4. Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL: Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage 2009;38:409-417.
5. Williams RL, Chen ML, Hauck WW: Equivalence approaches. Clin Pharmacol Ther 2002;72:229-237.
6. Knotknova H, Fine PG, Portenoy RK: Opioid rotation: The science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009;38:426-439.
7. Mahler DL, Forrest WH: Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975;42:602-607.
8. Eddy NB, Halbach H, Braenden OJ: Synthetic substances with morphine-like effect. Bull WHO 1956;14:353-402.
9. Eddy NB, Halbach H, Braenden OJ: Synthetic substances with morphine-life effect: Clinical experience, potency, side-effects, addiction liability. Bull WHO 1957;17: 569-863.
10. Lawlor P, Turner K, Hanson J, Bruera E: Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain 1997;72:79-85.
11. Dunbar PJ, Chapman CR, Buckley FP, Gavrin JR: Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain 1996;68:265-270.
12. Collins JJ, Geake J, Grier HE, Houck CS, Thaler HT, Weinstein HJ, Twum-Danso NY, Berde CB: Patient-controlled analgesia for mucositis pain in children: A three-period crossover study comparing morphine and hydromorphone. J Pediatr 1996;129:722-730.
13. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD: Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997;72:333-346.
14. MillerMG,McCarthy N, O'Boyle CA, Kearney M: Continuous subcutaneous infusion of morphine vs hydromorphone: A controlled trial. J Pain Symptom Manage 1999;18:9-16.
15. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E: Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-687.
16. Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E: The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 1999;7:265-270.
17. Watanabe S, Pereira J, Hanson J, Bruera E: Fentanyl by continuous subcutaneous infusion for the management of cancer pain: A retrospective study. J Pain Symptom Manage 1998;16:323-326.
18. Gordon DB, Stevenson KK, Griffie J, Muchka S, Rapp C, Ford-Roberts K: Opioid analgesic calculations. J Palliat Med 1999;2:209-218.
19. Gralow I: Cancer pain: An update of pharmacological approaches in pain therapy. Curr Opin Anaesthesiol 2002; 15:555-561.
20. Patanwala AE, Duby J, Waters D, Erstad BL: Opioid conversions in acute care. Ann Pharmacother 2007;41:255-267.